A limited sampling schedule to estimate mycophenolic acid area under the concentration-time curve in hematopoietic cell transplantation recipients

Journal of Clinical Pharmacology

Volumn 52, Issue 11, 2012, Pages 1654-1664

  Li, Hong ^a   Mager, Donald E ^a   Bemer, Meagan J ^b   Salinger, David H ^c,e   Vicini, Paolo ^c,f   Sandmaier, Brenda M ^b,d   Nash, Richard ^b,d   Mccune, Jeannine S ^b,d  

^a UNIVERSITY AT BUFFALO   (United States)

^b USA   (United States)

^c University of Washington   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e AMGEN INC   (United States)

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

hematopoietic cell transplantation; limited sampling schedule; Mycophenolic acid; population pharmacokinetics

Indexed keywords

MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG INFUSION; DRUG METABOLISM; FEMALE; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SAMPLING; SIMULATION;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; TIME FACTORS; YOUNG ADULT;

EID: 84868008306     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011429567     Document Type: Article

References (22)

1. Copelan EA.. Hematopoietic stem-cell transplantation. N Engl J Med. 2006 ; 354 (17). 1813-1826
2. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001 ; 97 (11). 3390-3400
3. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003 ; 102 (6). 2021-2030 (Pubitemid 37122375)
4. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Miller JS, Wagner JE.. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood. 2003 ; 102 (5). 1915-1919 (Pubitemid 37022593)
5. Bornhauser M, Schuler U, Porksen G, et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation. 1999 ; 67 (4). 499-504 (Pubitemid 29114207)
6. Nash RA, Johnston L, Parker P, et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2005 ; 11 (7). 495-505 (Pubitemid 40862446)
7. Staatz CE, Tett SE.. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007 ; 46 (1). 13-58 (Pubitemid 46091591)
8. Maris MB, Sandmaier BM, Storer BE, et al. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant. 2006 ; 12 (4). 454-465 (Pubitemid 43380962)
9. Giaccone L, McCune JS, Maris MB, et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood. 2005 ; 106 (13). 4381-4388 (Pubitemid 41775952)
10. Jacobson P, Rogosheske J, Barker JN, et al. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther. 2005 ; 78 (5). 486-500 (Pubitemid 41698903)
11. Osunkwo I, Bessmertny O, Harrison L, et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant. 2004 ; 10 (4). 246-258 (Pubitemid 38456203)
12. Haentzschel I, Freiberg-Richter J, Platzbecker U, et al. Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Bone Marrow Transplant. 2008 ; 42 (2). 113-120
13. van Hest RM, van Gelder T, Vulto AG, Mathot RA.. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet. 2005 ; 44 (10). 1083-1096 (Pubitemid 41356393)
14. Salinger DH, Blough DK, Vicini P, et al. A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients. Clin Cancer Res. 2009 ; 15 (16). 5280-5287
15. Savic RM, Karlsson MO.. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009 ; 11 (3). 558-569
16. de Winter BC, Mathot RA, Sombogaard F, et al. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease. Ther Drug Monit. 2010 ; 32 (5). 606-614
17. Saint-Marcoux F, Royer B, Debord J, et al. Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation. Clin Pharmacokinet. 2009 ; 48 (10). 667-675
18. Musuamba FT, Rousseau A, Bosmans JL, et al. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. Clin Pharmacokinet. 2009 ; 48 (11). 745-758
19. Ng J, Rogosheske J, Barker J, Weisdorf D, Jacobson PA.. A limited sampling model for estimation of total and unbound mycophenolic acid (MPA) area under the curve (AUC) in hematopoietic cell transplantation (HCT). Ther Drug Monit. 2006 ; 28 (3). 394-401 (Pubitemid 44314928)
20. Le Meur Y, Buchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007 ; 7 (11). 2496-2503 (Pubitemid 47566324)
21. Le Guellec C, Bourgoin H, Buchler M, et al. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin Pharmacokinet. 2004 ; 43 (4). 253-266 (Pubitemid 38429305)
22. Premaud A, Le Meur Y, Debord J, et al. Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit. 2005 ; 27 (3). 354-361 (Pubitemid 40770993)